Management

Bill Radvak

Interim Chief Executive Officer

Bill Radvak, co-founder of NervGen, has been the CEO and director of multiple start-up companies. He was a founder and the CEO of Response Biomedical, a publicly listed medical device company, which he led from its inception to a 90-employee sales and manufacturing company. Mr. Radvak received his Bachelor of Applied Science degree from the University of British Columbia.

Adam Rogers

Interim President

Adam Rogers, MD is a Principal of Boston based PFP Biosciences Holdings and a board-certified ophthalmologist specializing in diseases and surgery of the retina and vitreous. Dr. Rogers co-founded Hemera Biosciences in 2010, a clinical stage gene therapy biotech company targeting dry age-related macular degeneration. He assumed the role of Chief Executive Officer in 2017 and oversaw all aspects of the company until the Hemera assets were acquired in December 2020 by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Dr. Rogers graduated from Emory University College and Emory School of Medicine. 

From 2001 to 2020 he served as an Assistant Professor of Ophthalmology at the New England Eye Center of Tufts Medical Center (Boston, MA). Dr. Rogers has published 25 articles in peer reviewed journals and co-authored two textbooks and numerous chapters in major ophthalmic textbooks. Since 2007 he has served on the board of One Family Inc., an organization whose mission is to end homelessness in Massachusetts. He is a member of the Emory University Board of Trustees.

Dan Mikol​

Dan Mikol

Chief Medical Officer

Dan Mikol, MD, PhD, has over 25 years of experience in the pharmaceutical industry and as a practicing neurologist conducting clinical research. For the past 15 years, Dr. Mikol has had leadership roles in neuroscience clinical development. Prior to joining NervGen, he was Executive Director and Global Therapeutic Development Head, Neurology and Nephrology at Amgen. He was instrumental in the approval of Aimovig for migraine prevention in 2018. Prior to Amgen, Dr. Mikol was the development lead for Tysabri at Biogen and supported the Japan approval of Tysabri for relapsing multiple sclerosis in 2014. Prior to that, he held positions in senior clinical development and medical affairs in neuroscience at Novartis and EMD Serono.

For 12 years, Dr. Mikol was an active clinician and clinical researcher in the Department of Neurology at the University of Michigan, specializing in the treatment of multiple sclerosis, where he rose to the level of Associate Professor. Dr. Mikol was educated at the University of Chicago for both his MD and PhD, and was a Fulbright Scholar in Immunological Research at Ludwig Maximilian University of Munich, Germany.

Bill Adams​

Bill Adams

Chief Financial Officer

Bill Adams, CPA, CA, has over 25 years of strategic financial management experience that includes mergers and acquisitions, operations and capital markets in both Canada and the U.S., as well as corporate and operational finance having held a number of executive positions with high-growth technology and life sciences companies, including Chief Financial Officer roles at Anandia Laboratories Inc., Response Biomedical Corp., CellFor Inc., and AnorMED Inc. 

He had a leading role in the sale of AnorMED to Genzyme for $580 million and was instrumental in the sale of Anandia in 2018 for $118 million. Mr. Adams has been responsible for completing over $250 million in public and private equity financing, including listing on the TSX and NASDAQ, and over $750 million in mergers and acquisitions and technology licensing transactions. Mr. Adams is a Chartered Professional Accountant, CA and holds a Bachelor of Commerce from the University of British Columbia.

Nana Collett​

Nana Collett

Vice President, Program Management

Nana Collett, MS, MBA, has over 20 years experience managing biopharma product development programs from preclinical stage to Phase 3 across a range of therapeutic areas and modalities. Prior to joining NervGen, Ms. Collett has been an independent consultant and advisor to start-up companies.

Prior to that, Ms. Collett was VP Program Management at Genevant Sciences and a member of the start-up leadership team where she was responsible for development of a pipeline of over 10 internal and partnered RNA therapeutic products. She previously spent nine years with NASDAQ-listed company Arbutus Biopharma (formerly Tekmira Pharmaceutical), most recently as VP Project Management responsible for all development stage programs and alliances. Prior to that, Ms. Collet held diverse roles at commercial stage biotech company QLT in project management, new product planning, and business development. Ms. Collett has a BSc (Honours) in Biology from University of British Columbia, an M.S. in Ecosystem Science from the University of Washington, and an MBA in Management of Technology from Simon Fraser University.

Matvey Lukashev

Vice President, Research and Preclinical Development

Matvey Lukashev, PhD, has over 30 years of research experience in academia, industry, and non-profit biotech settings. Most recently, Dr. Lukashev served as Vice-President, Translational Sciences at the ALS Therapy Development Institute where he built and led a new translational research and drug discovery function encompassing patient genomics, stem cell biology, genome editing and phenotypic screening for biomarker, target and drug discovery in amyotrophic lateral sclerosis.

Prior to joining the ALS Therapy Development Institute, Dr. Lukashev held positions of increasing responsibility at Biogen, where he received the Biogen Idec Outstanding Achievement Award for his leadership of translational studies supporting clinical development of Tecfidera®. Dr. Lukashev obtained his doctorate in Cell Biology from the USSR Academy of Medical Sciences and received postdoctoral training at John Hopkins University and University of California, San Francisco.

Advisors

Jerry Silver, PhD​

Jerry Silver, PhD

Co-Inventor and Scientific Advisor

Dr. Silver is the Professor of Neurosciences at Case Western Reserve University’s School of Medicine and adjunct Professor in the Department of Neurosurgery at the Cleveland Clinic Foundation. He is credited in over 180 publications and is the recipient of several prestigious awards, including the Ameritec Prize for significant accomplishments toward a cure for paralysis. 

In 2003 he was also honored with the Christopher Reeve-Joan Irvine Research Medal (The Reeve-Irvine Medal) for critical contributions that may lead to the promotion of repair of the damaged spinal cord. Dr. Silver is an active advisor to NervGen, and his lab continues to conduct studies in concert with other academic institutions and partners to advance and evolve intracellular sigma peptide

Michael Davis

Michael Davis, Colonel (ret.) USAF, MC, MD, FACS, FRCS (Hon.)

Advisor

Colonel (ret.) Michael Davis, MD, FACS is recently retired after 26 years of military service, and has accumulated an extensive, rare knowledge base involving the clinical, scientific, operational and governmental programmatic domains. He has garnered numerous military and medical publications and awards, and serves as a reviewer for professional journals… 

…and is a Fellow of the American College of Surgeons. For the past seven years, Colonel (ret.) Davis has served in escalating Department of Defense programmatic roles as Deputy Commander, US Army Institute of Surgical Research, and culminating over the past three years, as Director, US Combat Casualty Care Research Program-the Department’s largest medical R&D program. With more than 30 years in the clinical and biomedical science field, Colonel (ret.) Davis provides services and expertise in trauma, regenerative/ restorative medicine, federal government relations, defense, health, cyber and national security.

Brian McAlister

Brian McAlister

Co-Founder and Advisor

A prolific start-up specialist, advisor, founder and angel investor to start-up companies, Mr. McAlister assists start-ups with raising capital and other activities. Over the past 30 years, Mr. McAlister has assisted over 25 early stage companies in various industries including biotechnology, enterprise software, and natural resources.